Author

J. M. Dziekan

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cell Biology· 2 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:drug response / drug discovery· 2 Organism:plant (other)· 2 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

Z. Bozdech· 2 shared A. B. Fisher· 1 shared A. Claës· 1 shared A. E. Barry· 1 shared A. F. Cowman· 1 shared A. Scherf· 1 shared B. E. Sleebs· 1 shared B. Kouskousis· 1 shared

Activity by Year

2022-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 19 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPharmacology & Toxicology

Z. Bozdech

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Aryl amino acetamides prevent the development of Plasmodium falciparum rings via inhibition of the lipid transfer protein PfSTART1

M. G. Dans, C. Boulet, G. M. Watson, W. Nguyen, J. M. Dziekan, C. Evelyn, K. Reaksudsan, S. Mehra, Z. Razook, N. D. Geoghegan, M. J. Mlodzianoski, C. D. Goodman, D. B. Ling, T. K. Jonsdottir, J. Tong, , P. R. Gilson

The paper identifies aryl amino acetamides that inhibit Plasmodium falciparum ring development by targeting PfSTART1, a lipid transfer protein, and shows these inhibitors block parasite transmission.

bioRxiv · Nov 2, 2023 · PreprintCell Biology

Quinazoline-quinoline bisubstrate inhibitors target eukaryotic translation initiation factor 3 in Plasmodium falciparum

I. Dobrescu, E. Hammam, J. M. Dziekan, A. Claës, L. Halby, P. Preiser, Z. Bozdech, P. B. Arimondo, A. Scherf, F. Nardella

This study identifies PfEIF3i as a target of quinoline-quinazoline inhibitors in Plasmodium falciparum, showing its essential role in parasite development and potential as an antimalarial drug target.

bioRxiv · Dec 10, 2022 · PreprintPharmacology & Toxicology

Human peroxiredoxin 6 is essential for malaria parasites and provides a host-based drug target

M. P. Wagner, P. Formaglio, O. Gorgette, J. M. Dziekan, C. Huon, I. Berneburg, S. Rahlfs, J.-C. Barale, S. I. Feinstein, A. B. Fisher, D. Menard, Z. Bozdech, R. Amino, L. Touqui, C. E. Chitnis

This study shows that human PRDX6 is essential for malaria parasite survival by repairing lipid peroxidation damage and that inhibiting it can kill parasites, including artemisinin-resistant strains.

bioRxiv · Apr 11, 2022Cell Biology